Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. - Wikidata - wikimedia - TriplyDB

Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.

Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.

http://www.wikidata.org/entity/Q33372766

about

Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review Introduction: thrombocytopenia in chronic liver disease -- treatment implications and novel approaches.Thrombocytopenia in patients with chronic hepatitis C: a possible role of HCV on platelet progenitor cell maturation.Low-dose pegylated interferon-alpha-2a monotherapy in elderly and/or cirrhotic patients infected with hepatitis C virus genotype-2 or genotype-1 low level infection.Liver disease, HIV and aging.Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection Hepatitis C in the elderly: epidemiology, natural history, and treatment The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study.Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.Management of chronic hepatitis C: consensus guidelines.Hepatitis C virus infection in the elderly: epidemiology, natural history and management.Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection Ribavirin in the treatment of chronic hepatitis C.Host factors determining the efficacy of hepatitis C treatment.Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis.Chronic hepatitis C in the aged: much ado about nothing or nothing to do?Hepatitis C Infection in the Elderly.A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort.Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C.Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation.Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C.Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more.Q56931621 Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study

P2860

Q27010548-365FCD24-A560-4669-9ADB-C1FDFF575AF5 Q33377122-4B7F7A4D-4C29-4B51-8FA8-475EFEE35402 Q33385876-26265903-1520-426B-B505-30AD0CB2C5CF Q33404899-E91AE27E-48FE-40D7-921D-C3325E906AB3 Q33810577-92176444-0AE7-4491-A9B1-1702A205A463 Q34067956-586660D2-7A46-4D5D-9B8D-8E3C38D5D000 Q34178971-03B88080-748C-497D-AE1C-866732350F50 Q34996746-904525AF-3E10-4605-A73D-6678D951D974 Q35055436-4E6DB491-C6BE-4656-8FE0-985F204A0ADB Q35764202-265B2365-E396-45F7-BC08-A17CB77074A6 Q35783876-30FB3F50-7795-4B76-9B6C-47C18942D5ED Q36849347-2C9DEE5E-4F86-4F6C-B5A1-EE152CC82D46 Q37053802-37BA6859-4011-47DB-9D09-2D4D1C17614E Q37130025-1A03B3B8-B2D3-4CCF-A03D-7E4A9CEF32B8 Q37195248-6ED8580C-D502-4E9C-A741-DDB6F644E5E5 Q38056077-2FEA4B14-615B-4D9C-B9AF-5B23C14C20B6 Q38160178-F92C4E3C-26D5-400F-83E1-4CB9C7B56AE2 Q38198992-48595B5D-4B33-42D4-99C9-1E68DF4292BC Q38501726-42BF15C8-08F9-4144-B27F-E47F888ECDB8 Q39751806-B9E13F1E-41AE-416D-9442-B658CE57EC1F Q40007121-8F897AE4-1193-4BDC-923F-902FF14C1993 Q42262075-C7B36445-BA41-41A1-9E5C-5F4988C69959 Q42612437-7B13C12E-6CC8-4B9C-BBE8-8AC8D2EF6745 Q45362984-36AC5DE8-4A44-4D72-9B2D-98AD7CF242B1 Q46104405-D862E921-C578-4CBC-B80A-828DE2A5FCFF Q50549693-8927B6C2-ACE6-405D-B417-BB39B96D9765 Q50550604-58592EAF-C8B9-478D-A8C4-58FF2D66DE3F Q50558655-5AF9D353-ED96-4D2D-AE51-4C9C58CF0EB0 Q56931621-966279A9-D5CD-4CBA-A66D-2BCA6EC65F61 Q57213193-8B9B3E05-9664-49BA-BE3E-E9E627C8A54D

P2860

Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.

http://www.wikidata.org/entity/Q33372766

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Elderly patients are at greate ...... viral therapy for hepatitis C.

@ast

Elderly patients are at greate ...... viral therapy for hepatitis C.

@en

type

label

Elderly patients are at greate ...... viral therapy for hepatitis C.

@ast

Elderly patients are at greate ...... viral therapy for hepatitis C.

@en

prefLabel

Elderly patients are at greate ...... viral therapy for hepatitis C.

@ast

Elderly patients are at greate ...... viral therapy for hepatitis C.

@en

P1433

Q33372766-261D25AA-498A-41E6-89EA-D5AAD1919A5B

P1476

Q33372766-062E7FAD-C13C-4278-8E4D-52A5A2A4388C

P2093

Q33372766-1D996B90-6093-4C11-87BE-A4841E24D51D

Q33372766-391A5EF8-CD66-4818-A4FC-1D7945D9A241

Q33372766-85BBAAB5-4D1C-4B62-B11C-3B3F3550CDB5

Q33372766-D956D89A-DF05-47A9-8133-2FB5DEDFEB60

P2860

Q33372766-048DF846-42B5-4DD5-ACAF-26AE1884EB7B

Q33372766-04CE616F-FF2C-448D-8B84-B363487B3F3C

Q33372766-0612DAE7-E4B7-49E1-B372-76F2A5146B0D

Q33372766-1427FCDB-8816-4CED-BE57-C914EB807F5E

Q33372766-25779E8E-A17E-4599-8A95-5ED5765E9DA2

Q33372766-35A9CD60-7A7D-4DDE-888B-B7E14C4E27B7

Q33372766-444DD30D-2B92-4231-8109-B56091CB1092

Q33372766-4B1E3202-D7AE-4C17-8654-68A335AE33C8

Q33372766-8AE64699-8070-4051-86D2-8941BE6822CC

Q33372766-A158198E-0D49-4178-A144-630D80A64B2C

P304

Q33372766-106CEA0C-D365-48D0-BDE4-FB6E029B6EB7

P31

Q33372766-6F914EA9-CE1D-4A29-93CF-9AF715F07535

P356

Q33372766-7A95B3DF-C7BF-45C5-9304-B005510FE35A

P407

Q33372766-8E5506C9-257A-41A5-A6E3-D90D27CA36BF

P433

Q33372766-0550EF6D-F00F-401F-A5E7-D7CFB5A48CAE

P478

Q33372766-5C36C791-C859-4E1A-922E-6BC4F34EC064

P577

Q33372766-11E3FF49-76BA-4CE0-B624-87D4EF7E1CEC

P698

Q33372766-ADD5FE98-F9FB-4CDF-8C4D-28742236C183

P932

Q33372766-78D17A69-60DA-4347-85B4-0742DEE05EBA

P356

P1433

Canadian Journal of Gastroenterology & Hepatology

P1476

Elderly patients are at greate ...... viral therapy for hepatitis C.

@en

P2093

C G Nudo

http://www.w3.org/2001/XMLSchema#string

M Deschênes

http://www.w3.org/2001/XMLSchema#string

N Hilzenrat

http://www.w3.org/2001/XMLSchema#string

P Wong

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

Understudied populations with hepatitis C.

Limited success of HCV antiviral therapy in United States veterans.

Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C.

Interferon therapy for patients more than 60 years of age with chronic hepatitis C.

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

Treatment of hepatitis C virus in elderly persons with interferon alpha.

P304

589-592

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2006/357259

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17001400

http://www.w3.org/2001/XMLSchema#string

P932

2659944

http://www.w3.org/2001/XMLSchema#string